{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T14:32:00Z","timestamp":1794407520451,"version":"4.9.0"},"reference-count":30,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T00:00:00Z","timestamp":1772064000000},"content-version":"unspecified","delay-in-days":56,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Neurol Open"],"accepted":{"date-parts":[[2026,1,22]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Preclinical evidence suggests targeting the mid-region of tau as a viable therapeutic strategy in diseases such as progressive supranuclear palsy (PSP): a rare, fatal, neurodegenerative tauopathy with no currently approved treatments. Bepranemab is a recombinant, humanised, full-length immunoglobulin G4 monoclonal antibody binding to a mid-region tau epitope. We assessed safety, tolerability and pharmacokinetics of bepranemab in participants with PSP.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      PSP003 (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT04185415\">NCT04185415<\/jats:ext-link>\n                      ), a multicentre, double-blind, placebo-controlled, phase 1b study, recruited participants in hospital settings across 13 centres. Participants (aged \u226540 years) met Movement Disorder Society-PSP criteria for possible\/probable PSP, could walk \u22655 steps with minimal\/no assistance and were stable on treatment for \u22652 weeks prior to baseline. Participants were randomised 3:1 to receive intravenous bepranemab (90\u2009mg\/kg) or placebo every 4\u2009weeks for 52 weeks. Primary endpoint: incidence of treatment-emergent adverse events (TEAEs) from baseline to last visit.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-five participants were enrolled (male: 44%; bepranemab n=18, placebo n=7). Seventeen (94.4%) in the bepranemab group reported \u22651\u2009TEAE (five participants; ten investigational medicinal product (IMP)-related TEAEs), versus placebo (n=7; 100%). In the bepranemab and placebo groups, respectively, three participants (16.7%) and one participant (14.3%) discontinued due to TEAEs. Incidence of IMP-related TEAEs and severe TEAEs was similar between groups; no deaths were reported. Reduction (80.41%) in mean free tau cerebrospinal fluid levels was observed in the bepranemab group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Multiple doses of bepranemab 90\u2009mg\/kg were well tolerated with an acceptable safety profile in participants with PSP. High target occupancy was observed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjno-2025-001396","type":"journal-article","created":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T14:00:17Z","timestamp":1772114417000},"page":"e001396","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Safety, tolerability and biomarker results of bepranemab in participants with progressive supranuclear palsy: a randomised, multicentre, double-blind, placebo-controlled, phase 1b trial"],"prefix":"10.1136","volume":"8","clinical-trial-number":[{"clinical-trial-number":"nct04185415","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03068468","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02985879","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03464227","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03605082","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04185415","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03464227","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04185415","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04658199","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03464227","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03605082","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04658199","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04185415","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"G\u00fcnter","family":"H\u00f6glinger","sequence":"first","affiliation":[{"name":"Department of Neurology, LMU University Hospital, Ludwig-Maximilians-Universit\u00e4t (LMU), Munich, Germany"},{"name":"Munich Cluster for Systems Neurology (SyNergy), Munich, Germany"},{"name":"German Center for Neurodegenerative Diseases e.V. (DZNE), Munich, Germany"},{"name":"Hannover Medical School, Hanover, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9758-5062","authenticated-orcid":false,"given":"Wim","family":"Vandenberghe","sequence":"additional","affiliation":[{"name":"Department of Neurology, UZ Leuven, Leuven, Belgium"},{"name":"Department of Neurosciences, KU Leuven, Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Woitalla","sequence":"additional","affiliation":[{"name":"Contilia Gruppe, Essen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Christophe","family":"Corvol","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, Paris Brain institute \u2013 ICM, Assistance Publique \u2013 H\u00f4pitaux de Paris, Inserm, CNRS, Department of Neurology, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Van Tricht","sequence":"additional","affiliation":[{"name":"UCB, Braine-l\u2019Alleud, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin","family":"Ewen","sequence":"additional","affiliation":[{"name":"UCB, Slough, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Van Den Steen","sequence":"additional","affiliation":[{"name":"UCB, Braine-l\u2019Alleud, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Rebollo Mesa","sequence":"additional","affiliation":[{"name":"UCB, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Germani","sequence":"additional","affiliation":[{"name":"UCB, Braine-l\u2019Alleud, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"Garric","sequence":"additional","affiliation":[{"name":"UCB, Braine-l\u2019Alleud, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasmin","family":"Arnould","sequence":"additional","affiliation":[{"name":"UCB (contracted via Veramed Ltd, Twickenham, UK), Braine-l\u2019Alleud, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joby","family":"Jose","sequence":"additional","affiliation":[{"name":"UCB, Slough, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Strong","sequence":"additional","affiliation":[{"name":"UCB, Smyrna, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4853-7339","authenticated-orcid":false,"given":"Steven","family":"De Bruyn","sequence":"additional","affiliation":[{"name":"UCB, Braine-l\u2019Alleud, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1218-5420","authenticated-orcid":false,"given":"Tim J","family":"Buchanan","sequence":"additional","affiliation":[{"name":"UCB, Braine-l\u2019Alleud, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,2,26]]},"reference":[{"key":"2026051208152455000_8.1.e001396.1","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-019-02087-9"},{"key":"2026051208152455000_8.1.e001396.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2017.03.011"},{"key":"2026051208152455000_8.1.e001396.3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1750-3639.1999.tb00550.x"},{"key":"2026051208152455000_8.1.e001396.4","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-28896-3","article-title":"Tau deposition patterns are associated with functional connectivity in primary tauopathies","volume":"13","author":"Franzmeier","year":"2022","journal-title":"Nat Commun"},{"key":"2026051208152455000_8.1.e001396.5","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-021-00541-5"},{"key":"2026051208152455000_8.1.e001396.6","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-015-1839-9"},{"key":"2026051208152455000_8.1.e001396.7","doi-asserted-by":"publisher","DOI":"10.1038\/nature23002"},{"key":"2026051208152455000_8.1.e001396.8","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-020-02158-2"},{"key":"2026051208152455000_8.1.e001396.9","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-023-02853-3","article-title":"Tau and neuroinflammation in Alzheimer\u2019s disease: interplay mechanisms and clinical translation","volume":"20","author":"Chen","year":"2023","journal-title":"J Neuroinflammation"},{"key":"2026051208152455000_8.1.e001396.10","unstructured":"Agarwal S , Gilbert R . Progressive supranuclear palsy. Treasure Island, FL: StatPearls Publishing, 2023."},{"key":"2026051208152455000_8.1.e001396.11","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26987"},{"key":"2026051208152455000_8.1.e001396.12","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awh488"},{"key":"2026051208152455000_8.1.e001396.13","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30489-0"},{"key":"2026051208152455000_8.1.e001396.14","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01455-x"},{"key":"2026051208152455000_8.1.e001396.15","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1001\/jamaneurol.2022.1375","article-title":"Safety and efficacy of semorinemab in individuals with prodromal to mild Alzheimer disease: a randomized clinical trial","volume":"79","author":"Teng","year":"2022","journal-title":"JAMA Neurol"},{"key":"2026051208152455000_8.1.e001396.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2004.08.014"},{"key":"2026051208152455000_8.1.e001396.17","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2018.00027","article-title":"Relevance of phosphorylation and truncation of tau to the etiopathogenesis of Alzheimer\u2019s disease","volume":"10","author":"Zhou","year":"2018","journal-title":"Front Aging Neurosci"},{"key":"2026051208152455000_8.1.e001396.18","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-018-1948-2"},{"key":"2026051208152455000_8.1.e001396.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2018.02.015"},{"key":"2026051208152455000_8.1.e001396.20","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jproteome.5b01001"},{"key":"2026051208152455000_8.1.e001396.21","doi-asserted-by":"publisher","DOI":"10.1002\/ana.26620"},{"key":"2026051208152455000_8.1.e001396.22","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02443-z"},{"key":"2026051208152455000_8.1.e001396.23","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awz100"},{"key":"2026051208152455000_8.1.e001396.24","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s00401-018-1911-2","article-title":"Epitope determines efficacy of therapeutic anti-Tau antibodies in a functional assay with human Alzheimer Tau","volume":"136","author":"Courade","year":"2018","journal-title":"Acta Neuropathol"},{"key":"2026051208152455000_8.1.e001396.25","doi-asserted-by":"publisher","DOI":"10.1016\/0022-3956(75)90026-6"},{"key":"2026051208152455000_8.1.e001396.26","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-011-9232-2"},{"key":"2026051208152455000_8.1.e001396.27","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1007\/s10928-019-09641-8","article-title":"A translational platform PBPK model for antibody disposition in the brain","volume":"46","author":"Chang","year":"2019","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"2026051208152455000_8.1.e001396.28","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awm032"},{"key":"2026051208152455000_8.1.e001396.29","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.parkreldis.2018.06.018","article-title":"Serum neurofilament light chain in progressive supranuclear palsy","volume":"56","author":"Donker Kaat","year":"2018","journal-title":"Parkinsonism Relat Disord"},{"key":"2026051208152455000_8.1.e001396.30","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S1474-4422(19)30139-5","article-title":"Safety of the tau-directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo-controlled, multiple ascending dose phase 1b trial","volume":"18","author":"Boxer","year":"2019","journal-title":"Lancet Neurol"}],"container-title":["BMJ Neurology Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjno-2025-001396","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T15:16:00Z","timestamp":1778598960000},"score":1,"resource":{"primary":{"URL":"https:\/\/neurologyopen.bmj.com\/lookup\/doi\/10.1136\/bmjno-2025-001396"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,2,26]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1136\/bmjno-2025-001396"],"URL":"https:\/\/doi.org\/10.1136\/bmjno-2025-001396","relation":{},"ISSN":["2632-6140"],"issn-type":[{"value":"2632-6140","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}